Please try another search
Celyad Oncology SA, formerly Celyad SA is a Belgium-based company. The Company is a clinical-stage biotechnology company focuses on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer. The Company develops allogeneic and autologous CAR T cell therapy candidates for cancer patients with hematological malignancies and solid tumors. The Company's product, CYAD-101 is a NKG2D receptor-based CAR T, which incorporates non-gene edited allogeneic TIM technology, for the treatment of refractory metastatic colorectal cancer (mCRC). It also develops short hairpin RNA (shRNA)-based allogeneic CAR T candidate CYAD-211 for the treatment of relapsed or refractory multiple myeloma (r/r MM). Its autologous CAR T franchise is evaluating NKG2D receptor CAR T candidate CYAD-02 for the treatment of relapsed or refractory acute myeloid leukemia (r/r AML) and myelodysplastic syndromes (MDS).
Name | Age | Since | Title |
---|---|---|---|
Maria Koehler | 64 | 2020 | Independent Director |
Hilde Windels | 57 | 2018 | Independent Chairwoman of the Board |
Serge Goblet | 65 | 2008 | Non-Executive Director |
Margo R. Roberts | 68 | 2018 | Member of Scientific Advisory Board |
Hinrich Abken | - | 2016 | Member of Scientific Advisory Board |
Marco L. Davila | - | 2016 | Member of Scientific Advisory Board |
Marina Udier Blagovic | - | 2020 | Independent Director |
Gerry Graham | - | - | Member of Scientific Advisory Board |
Ami Patel Shah | - | 2021 | Non-Executive Director |
Christopher LiPuma | - | 2022 | Non-Executive Director |
Ann Ager | - | - | Member of Scientific Advisory Board |
Jean-Christophe Marine | - | - | Member of Scientific Advisory Board |
Dominic G. Piscitelli | 48 | 2020 | Independent Director |
John Campbell | - | - | Member of Scientific Advisory Board |
Michel E. J. Lussier | 67 | 2007 | Co-Founder, Interim CEO & Executive Director |
Jonathan James | - | 2024 | Non-Executive Director |
Sage Mandel | - | 2024 | Non-Executive Director |
Andrea Gothing | - | 2024 | Non-Executive Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review